Objective: Invasive micropapillary carcinoma of the breast is a distinct variant of breast cancer. In the present study, we analyzed potential immunophenotypic changes in invasive micropapillary carcinoma. Methods: Specimens from 15 patients with invasive micropapillary carcinoma were analyzed using clinicopathological and immunohistochemical methods. We also examined the relationship between clinicopathological factors using the Ki-67 labeling index. Results: Immunohistochemical staining for cytoplasmic p63 expression was seen in four (27%) tumors, and p63 nuclear expression was also observed in four (27%) tumors. Involucrin and 34betaE12 were expressed in the invasive micropapillary carcinoma component of nine (60%) and four (27%) tumors, respectively. Cytokeratin 5/6 was expressed in three (20%) tumors and cytokeratin 14 staining was negative in all tumors. In one tumor (case 3), vimentin, epithelial membrane antigen and cytokeratin 8/18 were co-expressed. Four tumors (27%) were negative for the estrogen receptor/progesterone receptor/HER2. However, 11 out of 15 (73%) tumors were positive for the estrogen receptor. The Ki-67 labeling index was significantly higher in cases with p63 tumor expression than in those without (P , 0.0001), and also higher in cases with lymph node metastasis than in cases without (P ¼ 0.0029). Conclusions: Nuclear expression of p63, involucrin and 34betaE12 were detected indicating squamous differentiation. Cytoplasmic p63 expression was also identified. The fact that the Ki-67 labeling index was significantly higher in such cases may have been associated with the aggressive behavior of these tumors. Our findings suggest that the characteristic morphology of invasive micropapillary carcinomas may be due to immunophenotypical and oncogenic changes.
INTRODUCTION
Invasive micropapillary carcinoma (IMPC) of the breast is a relatively rare, distinct variant of breast cancer (1) . This carcinoma has been reported to show lymphovascular invasion, lymph node metastasis, local recurrence and distant metastasis at a relatively high frequency, thereby exhibiting more aggressive behavior than invasive ductal carcinoma (IDC-NOS) (2 -4) . IMPC has also been characterized immunohistochemically by a high rate of p53 positivity, a lower frequency of estrogen receptor (ER) expression and no detectable expression of basal-like markers (4) . Histologically, IMPC is composed of small clusters of tumor cells lying within clear stromal spaces resembling dilated vascular channels (5) . Immunohistochemically, IMPC exhibits an 'inside-out' pattern of EMA expression (6) . In other words, lineal deposits of EMA substances can be seen rimming externally clusters and pseudo-tubules of cancer cells, indicating the inversion of the cellular polarity. This phenomenon is referred to as an inside-out growth pattern (6) .
The characteristic appearance of cancer cell clusters shrinking and floating in stromal spaces may suggest phenotypic changes in the cancer cells. In addition, as seen in pathological specimens evaluated on a daily basis, we speculated that some IMPCs exhibit small solid-nests as squamoid-like features. Tsuda et al. (7) reported that 22% of IDCs showed squamoid features. Recent studies have shown epithelial-mesenchymal transition (EMT) (8, 9) , expression profile-based identification of the basal-like phenotype (10,11) and nuclear and cytoplasmic p63 expression in breast cancer cells (12, 13) . In the present study, we analyzed the immunophenotypical characterization of IMPC cells using immunohistochemical methods. EMA was used to confirm the inside-out pattern, and as well as an epithelial marker to demonstrate EMT. Cytokeratin (CK) 8/18 was employed as an epithelial marker and vimentin as a mesenchymal marker for EMT. CK5/6, 14 and 34betaE12 were utilized as basal-like markers. Involucrin and p63(n) and 34betaE12 were used to evaluate squamous differentiation. c-kit was employed to establish whether or not the IMPCs related to a undifferentiated 'stem-cell-like' carcinoma (14) . We also examined clinicopathological factors using the Ki-67 labeling index (LI) as an indicator of tumor aggressiveness.
PATIENTS AND METHODS

TUMOR SPECIMENS
Breast tumors surgically removed (including one biopsy specimen) from 15 patients diagnosed with IMPC at the Kurume University Medical Center (Kurume, Japan) and at the Social Insurance Kurume Daiichi Hospital (Kurume, Japan) were used in the study. They were classified as a 'pure' type (comprising a 100% IMPC component) and a 'mixed' type (comprising a 50% IMPC component and IDC-NOS). The tumors were analyzed using the clinicopathological and immunohistochemical methods.
IMMUNOHISTOCHEMICAL METHODS
Each tissue block was embedded in paraffin and stained with hematoxylin and eosin (H&E). Immunohistochemically, the expression and the localization of the following antigens were examined using a Maxitag w Universal Kit [Shandon-lipshaw (Immunon), Pittsburgh, PA, USA]: CK8, 18, 5/6, 14, 34betaE12, involucrin, c-kit, vimentin and p63 (Table 1) . Strong immunoreactivity of a marker protein, regardless of the extent, and moderate-to-weak expression in more than 10% of the total tumor area was defined as 'positive' staining. Moderate-to-weak expression in ,10% of the total tumor and no expression was defined 'negative' staining. With respect to p63 expression, nuclear expression in myoepithelial cells in and/or surrounding the tumor was 
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Immunoprofile of invasive micropapillary carcinoma used as an internal control. Expression of the ER, progesterone receptor (PgR) and HER2/neu (C-erbB-2) was examined using the Ventana I-VIEW Breast Panel (Ventana Medical Systems, Tucson, AZ, USA). The anti-D2-40 antibody was used to confirm the presence of lymph vessels, and anti-EMA was used to confirm the presence of an inside-out pattern (6) of IMPC cells in all cases (Table 1) . Ki-67 staining of the tumor cells was recorded as the number of positive nuclei divided by the total number of tumor cells and was expressed as a percentage, and a mean + SD of five views was obtained as the LI (%). We examined the Ki-67 LI and compared the IMPC and IDC-NOS components in mixed-type tumors. We also investigated the relationship between the clinicopathological factors and the Ki-67 LI.
STATISTICAL ANALYSIS
Data are expressed as the mean + SD. Comparison of the Ki-67 LI of the IMPC and IDC-NOS components in mixedtype tumors and correlations between the Ki-67 LI and p63 expression, lymphatic invasion and lymph node metastasis were performed using the Mann -Whitney U-test.
RESULTS
CLINICOPATHOLOGICAL CHARACTERISTICS
Eight patients were diagnosed with pure IMPC and seven with mixed IMPC. The mean age of the patients was 60.1 + 14.0 years. The diameter of the tumors on pathological examination was 2.3 + 1.8 cm; nine patients had tumors of ,1.5 cm in size and two patients had tumors of ,1 cm in size. Three, six and six tumors exhibited nuclear grades (NG) (15) of 3, 2 and 1, respectively. Small micropapillary clusters of cancer cells were observed floating and proliferating in the lumen surrounded by scanty stroma; small solid nests of IPMC cells were also observed ( Fig. 1A and B) . Lymphatic invasion and lymph node metastasis were observed in 10 (67%) and 7 (47%) of 15 patients, respectively (Table 2) .
IMMUNOHISTOCHEMICAL FINDINGS
Cytoplasmic p63 expression and nuclear p63 expression were seen in 4 (27%) and 4 (27%) tumors, respectively ( Fig. 2A  and B) . Staining for involucrin was positive in the IMPC component of nine (60%) tumors (Fig. 2C) . Staining for Jpn
34betaE12 was positive in four (27%) tumors (Fig. 2D ). CK5/6 staining was positive in 3 (20%) tumors and CK14 staining was negative in all tumors. CK8 and CK18 staining were positive in all tumors. One tumor (case 3) co-expressed CK8/18, EMA and vimentin (Fig. 2E ) and was focally positive for 34betaE12. All tumors were negative for c-kit. Virtually no difference was noted in the expression of marker protein between the ductal and IMPC components of mixed tumors. However, the expression of CK5/6 was stronger in the IMPC component than in the ductal component of two CK5/6-positive tumors. One of the basal cell-specific CK antibodies 34betaE12 was positive in the IMPC component of one tumor and the ductal component of one tumor. EMA was confirmed to have an inside-out pattern in IMPC cells in all cases. Four tumors (27%) were negative for ER/PgR/ HER2, but 11 of 15 (73%) were positive for ER (Table 3 ). 
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RELATIONSHIP BETWEEN KI-67 LI AND CLINICOPATHOLOGICAL FEATURES
The total Ki-67 LI for all IMPC cases was 28.7 + 19.5 ( Table 4 ). The IDC component of mixed-type tumors (Cases 9 -15) had a Ki-67 LI of 16.7 + 9.4. The LI of IMPCs was significantly higher than the LI of the IDC component of the mixed type (P ¼ 0.02, Cases 9 -15). The Ki-67 LI of the IMPC component was significantly higher than that of the IDC-NOS component in Cases 10 and 12 with mixed-type tumors (Table 4 ). In cases with tumor expression of p63, the Ki-67 LI was significantly higher than those with no p63 expression (P , 0.0001); the LI was also found to be higher in cases with lymph node metastasis than those with no metastasis (P ¼ 0.0029). On the other hand, the Ki-67 LI was comparable in cases with or without lymphovascular invasion (P , 0.132).
DISCUSSION
In the present study, cytoplasmic expression of p63 was identified in some IMPC tumors. Cytoplasmic p63 expression in IMPCs has not been reported previously. However, cytoplasmic localization of p63 has been reported in lung tumors and is associated with poor patient survival (16) . It is also correlated with high tumor grade in meningiomas (17) and increased mortality in prostate cancer patients (18) . The cytoplasmic staining of p63, a transcription factor involved in transactivation, apoptosis and proliferation that usually stains in the nucleus, may suggest an altered and potentially oncogenic function (18) . The clinical significance of cytoplasmic p63 expression in breast cancer is unknown, but a similar morphological and 
2, negative; þ, positive; 34b, 34betaE12; VIM, vimentin; INV, involucrin; P63n, p63 nuclear expression; P63c, p63 cytoplasmic expression. Case 9 -15: invasive micropapillary carcinoma component/invasive ductal carcinoma component. 
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immunohistochemical profile of cytoplasmic p63 expression in secretory carcinomas and pregnancy-associated carcinomas has been reported (12, 13) . IMPCs have been reported to exhibit more aggressive behavior than IDC-NOS (2 -4), and this might be supported by the fact that cytoplasmic p63 expression and lymph node metastasis were associated with high Ki-67 LIs. Additionally, the Ki-67 LI was found to be significantly higher in micropapillary components than in IDC components in mixed type in the present study. The p63 gene is considered to have a role in maintaining stem cell or reserve cell populations in various normal epithelial cells (16) . These include the basal and myoepithelial cells of 'two-layer' epithelialmyoepithelial structures in the breast. Thus, IMPCs that show an inside-out pattern may be the result of the oncogenic effect of p63 in disrupting the maintenance system of these epithelial and myoepithelial cells.
In the present study, some cases exhibited the expression of nuclear p63. Previous studies have linked the nuclear expression of p63 to squamous cell differentiation and to squamous cell carcinomas (19) . We speculate that the characteristic 'shrinking and floating' morphology of some IMPCs observed in H&E-stained sections represent small solid nest-like squamous metaplasia (Fig. 1B) . In the present study, involucrin (60%), 34betaE12 (27%) and p63 nuclear expression were found in IMPC cells. p63 expression was seen in 27% of cases in our series, which was higher than a level of 0.6% reported in IDC-NOS (20), but lower than the level (51%) reported by Weigelt et al. (21) . Tsuda et al. (7) reported the following: 22% and 27% of breast cancers exhibited squamoid features and involucrin expression, respectively; squamoid features and involucrin expression were correlated with each other; and involucrin expression was associated with a higher incidence of regional recurrence. Thus, the characteristic small, solid morphological structure sometimes seen in IMPCs might be due to squamous differentiation, in addition to the oncogenic effect of p63 in disrupting the maintenance system of these epithelial and myoepithelial cells.
Recent gene profiling studies have reported a basal-like subtype, which has been identified by immunohistochemical staining for CK5/6 and 14 (11, 12) . Kim et al. (4) reported that IMPC did not show basal-like features. In the present study, staining for CK14 was negative in all cases. Staining for CK5/6 and 34betaE12 were focally positive in the IMPC component in three and four cases, respectively. Four cases were negative for the ER/PgR/HER2. Kim et al. (4) reported a low rate of ER expression. However, the ER was positive in 11 cases in the present study. Thus, the association with the basal-like subtype does not seem to be strong, but seven tumors in the present study were relatively small or were of Grade I. Their changes in expression may occur in a stepwise fashion according to the factors such as tumor size and grade. Although c-kit-positive 'stem-cell-like' carcinomas have been reported (14) , c-kit expression was not identified in our series. We speculate that IMPC does not relate to the c-kit-positive 'stem-cell-like' carcinomas.
Interestingly, CK8/18 (epithelial markers), EMA and vimentin (mesenchymal marker) were co-expressed in IMPC in one case. Recent studies have suggested the presence of EMT in breast cancer cells and the existence of progenitor cells (8, 9) . Therefore, it is possible that EMT is sometimes involved in IMPC development. Furthermore, Case 3 was negative for ER/PgR/HER2, even though basal CK markers were negative.
In the present study, lymphovascular invasion and lymph node metastasis were observed at a relatively high frequency, as has been reported previously (2 -4). They were even seen in Cases 1 and 7, in which the histological tumor size was relatively small. The Ki-67 LI was also significantly higher in cases with lymph node metastasis than in cases without, in line with the aggressiveness of the tumors in these cases. At the molecular/gene level, IMPC has been reported to be a distinct entity from IDC-NOS (22) . We believe that the present study is the first to report the cytoplasmic expression of p63 in IMPCs. Our results suggest that p63 cytoplasmic expression may be an altered and potentially oncogenic function for the mislocalized protein in IMPC cells, i.e. cytoplasmic p63 expression was associated with increased proliferation activity (Ki-67), and may be disrupted the maintenance system of epithelial and myoepithelial cells. In addition, nuclear expression of p63, involucrin and 34betaE12 were also seen in IMPCs indicating squamous differentiation. Our findings may also suggest EMT or a change to basal-like features in some cases. In conclusion, our results suggest that the characteristic morphology of IMPCs may be due to immunophenotypic and oncogenic changes in the cancer.
